Accelerating antimalarial drug discovery through collective expertise and resources

Today, the Malaria Drug Accelerator (MalDA) is a consortium of 18 different laboratories who have individually developed and maintained many of the platforms that contribute to early stage anti-malaria drug development including target discovery and validation.

Our Mission

Members

See All Members

Dr. Gang Liu

Gates Foundation

Dr. Elizabeth A. Winzeler

Winzeler Lab at the University of California, San Diego

Dr. Brice Campo

Medicines for Malaria Venture (MMV)

Dr. Dyann F. Wirth

Wirth Lab at Harvard T.H. Chan School of Public Health

Dr. David Fidock

Fidock Lab at Columbia University Irving Medical Center

Dr. Daniel Goldberg

Goldberg Lab at Washington University

Dr. Javier Gamo

GlaxoSmithKline

Dr. Marcus Lee

Lee Lab at Wellcome Sanger Institute

Prof. Jacquin C. Niles

Niles Lab at Massachusetts Institute of Technology

Dr. Nobutaka Kato

The Global Health Drug Discovery Institute

Prof. Ian Gilbert

Wellcome Centre for Anti-Infectives Research (WCAIR), at the University of Dundee

Prof. Manuel Llinás

Llinas Lab at Pennsylvania State University

Prof. Kelly Chibale

Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town

Dr. Koen Dechering

TropIQ Health Sciences

Dr. Case McNamara

Calibr-Skaggs Institute for Innovative Medicines

Dr. Philip Hipskind

Lgenia

Dr. Thierry Diagana

Novartis Institutes for Biomedical Research

News & Announcements

Read the latest news and announcements from the Malaria Drug Accelerator Consortium and related members.

Phenotype Database

Single nucleotide variants (SNVs) and insertion-deletion events (INDELs) observed in whole genome analysis from various MalDA’s compound selections with shown antimalarial activity can be access in the phenotype database, including a list of peer-reviewed studies in which the compound was a member.

Learn More

Read about MalDA’s mission and approach

About Us

Prioritization of Molecular Targets for Antimalarial Drug Discovery.

October 8, 2021

There is a shift in antimalarial drug discovery from phenotypic screening toward target-based approaches, as more potential drug targets are being validated in species. Given the high attrition rate and high cost of drug discovery, it is important to select the targets most likely to deliver progressible drug candidates. In…
Design of proteasome inhibitors with oral efficacy in vivo against and selectivity over the human proteasome.

September 28, 2021

The proteasome is a potential antimalarial drug target. We have identified a series of amino-amide boronates that are potent and specific inhibitors of the 20S proteasome (20S) β5 active site and that exhibit fast-acting antimalarial activity. They selectively inhibit the growth of compared with a human cell line and exhibit…
Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention.

February 17, 2022

We identify the Plasmodium falciparum acetyl-coenzyme A synthetase (PfAcAS) as a druggable target, using genetic and chemical validation. In vitro evolution of resistance with two antiplasmodial drug-like compounds (MMV019721 and MMV084978) selects for mutations in PfAcAS. Metabolic profiling of compound-treated parasites reveals changes in acetyl-CoA levels for both compounds. Genome editing…

Accelerating antimalarial drug discovery through collective expertise and resources

Members

News & Announcements

Phenotype Database

Learn More

Recent Publications

Prioritization of Molecular Targets for Antimalarial Drug Discovery.

Design of proteasome inhibitors with oral efficacy in vivo against and selectivity over the human proteasome.

Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention.